Activation of PPARγ by SB Cells® Treatment for Type 2 Diabetes Patients: A Case Study

Abstract

et al. Activation of PPARγ by SB cells® treatment for type 2 diabetes patients: a case study. Stem Cells Regen Med. 2017; 1(2) 003: 1-4. ABSTRACTManagement of blood glucose levels is vital for the health and well-being of those with type 2 diabetes mellitus. Current research has identified novel targets for regulating glucose and fat metabolism, with peroxisome proliferatoractivated receptors (PPAR) emerging as a candidate in treating type 2 diabetes. Diabetes mellitus medications may target the PPAR pathway, and the class of thiazolidinediones is a popular treatment that functions as PPARγ agonists. While this treatment is an established method for lowering blood glucose through increasing insulin sensitivity, patients may experience serious adverse effects such as hepatotoxicity and heart failure. Therefore, there is a need for safe and effective type 2 diabetes therapies. Stem cell research regarding diabetes mellitus has provided promising therapies for improving insulin sensitivity and normalizing blood glucose. The objective of this study is to examine the effects of the StemBios stem cell therapy on maintaining healthy glucose levels through the PPARγ pathway in type 2 diabetes patients. In this study, we tracked PPARγ levels before and after intravenous SB cells® (StemBios cell) infusion. The treatment led to an increase in PPARγ levels and stabilized blood glucose levels after the treatment, suggesting that the SB cells® treatment offers a therapeutic benefit for those with type 2 diabetes.